


**MAIMON RESEARCH LLC**

**ARTIFICIAL INTELLIGENCE LARGE LANGUAGE  
MODEL INTERROGATION**



**REPRESENTATIONAL MEASUREMENT FAILURE IN  
HEALTH TECHNOLOGY ASSESSMENT**

**UNITED STATES: *PHARMACOECONOMICS* AND THE  
ABSENCE OF MEASUREMENT**

**Paul C Langley Ph.D Adjunct Professor, College of Pharmacy, University of  
Minnesota, Minneapolis, MN**

**LOGIT WORKING PAPER No 18 JANUARY 2026**

**[www.maimonresearch.com](http://www.maimonresearch.com)**

**Tucson AZ**

## FOREWORD

### HEALTH TECHNOLOGY ASSESSMENT: A GLOBAL SYSTEM OF NON-MEASUREMENT

This Logit Working Paper series documents a finding as extraordinary as it is uncomfortable: health technology assessment (HTA), across nations, agencies, journals, and decades, has developed as a global system of non-measurement. It speaks the language of numbers, models, utilities, QALYs, “value for money,” thresholds, discounting, incremental ratios, extrapolations, and simulations. It demands arithmetic at every turn, multiplication, division, summation, aggregation, discounting, yet it never once established that the quantities to which these operations are applied are measurable. HTA has built a vast evaluative machinery on foundations that do not exist. The probabilities and normalized logits in the country reports that follow provide the empirical confirmation of this claim. They show, with unsettling consistency, that HTA presents a world of measurement failure.

The objective of this study is to assess, using a standardized 24-statement diagnostic instrument, the extent to which the international journal *Pharmacoconomics* recognizes and applies the axioms of representational measurement theory. The analysis treats the journal not merely as a publication outlet, but as an epistemic authority whose editorial standards, reviewer expectations, and methodological preferences shape what counts as legitimate evidence in health technology assessment. The study examines whether measurement validity is treated as a prerequisite for arithmetic operations, such as multiplication, aggregation, and ratio construction, or whether arithmetic is permitted independently of measurement.

A secondary objective is structural and explanatory. Because *Pharmacoconomics* functions as a training ground for HTA analysts, a reference point for agencies, and a methodological benchmark for academic programs, its measurement beliefs have consequences far beyond individual articles. The study therefore asks whether the journal operates as a corrective force that enforces scientific measurement discipline, or whether it institutionalizes a belief system in which false measurement is normalized and reproduced.

The findings show that *Pharmacoconomics* systematically rejects the axioms of representational measurement while strongly endorsing the numerical propositions required to sustain cost-utility analysis, QALYs, and reference-case simulation modeling. Fundamental requirements, such as the necessity that measurement precede arithmetic, that multiplication requires ratio measures, and that arithmetic be licensed by scale properties, collapse to the lowest end of the endorsement scale. In contrast, false propositions essential to the journal’s dominant methodology including that QALYs are ratio measures, that they are dimensionally homogeneous, and that they can be aggregated are endorsed at very high probability.

The journal does not merely tolerate measurement failure; it depends on it. Its methodological coherence is achieved by granting arithmetic autonomy from measurement. This inversion explains the exclusion of Rasch measurement, the routine acceptance of summated ordinal scores as ratio measures, and the treatment of simulation outputs as decision-relevant evidence. The result

is a stable but scientifically indefensible knowledge base that continues to shape HTA practice globally.

The modern articulation of this principle that measurement precedes arithmetic can be traced to Stevens' seminal 1946 paper, which introduced the typology of nominal, ordinal, interval, and ratio scales <sup>1</sup>. Stevens made explicit what physicists, engineers, and psychologists already understood: different kinds of numbers permit different kinds of arithmetic. Ordinal scales allow ranking but not addition; interval scales permit addition and subtraction but not multiplication; ratio scales alone support multiplication, division, and the construction of meaningful ratios. Utilities derived from multiattribute preference exercises, such as EQ-5D or HUI, are ordinal preference scores; they do not satisfy the axioms of interval measurement, much less ratio measurement. Yet HTA has, for forty years, treated these utilities as if they were ratio quantities, multiplying them by time to create QALYs and inserting them into models without the slightest recognition that scale properties matter. Stevens' paper should have blocked the development of QALYs and cost-utility analysis entirely. Instead, it was ignored.

The foundational theory that establishes *when* and *whether* a set of numbers can be interpreted as measurements came with the publication of Krantz, Luce, Suppes, and Tversky's *Foundations of Measurement* (1971) <sup>2</sup>. Representational Measurement Theory (RMT) formalized the axioms under which empirical attributes can be mapped to numbers in a way that preserves structure. Measurement, in this framework, is not an act of assigning numbers for convenience, it is the discovery of a lawful relationship between empirical relations and numerical relations. The axioms of additive conjoint measurement, homogeneity, order, and invariance specify exactly when interval scales exist. RMT demonstrated once and for all that measurement is not optional and not a matter of taste: either the axioms hold and measurement is possible, or the axioms fail and measurement is impossible. Every major construct in HTA, utilities, QALYs, DALYs, ICERs, incremental ratios, preference weights, health-state indices, fails these axioms. They lack unidimensionality; they violate independence; they depend on aggregation of heterogeneous attributes; they collapse under the requirements of additive conjoint measurement. Yet HTA proceeded, decade after decade, without any engagement with these axioms, as if the field had collectively decided that measurement theory applied everywhere except in the evaluation of therapies.

Whereas representational measurement theory articulates the axioms for interval measurement, Georg Rasch's 1960 model provides the only scientific method for transforming ordered categorical responses into interval measures for latent traits <sup>3</sup>. Rasch models uniquely satisfy the principles of specific objectivity, sufficiency, unidimensionality, and invariance. For any construct such as pain, fatigue, depression, mobility, or need, Rasch analysis is the only legitimate means of producing an interval scale from ordinal item responses. Rasch measurement is not an alternative to RMT; it is its operational instantiation. The equivalence of Rasch's axioms and the axioms of representational measurement was demonstrated by Wright, Andrich and others as early as the 1970s. In the latent-trait domain, the very domain where HTA claims to operate; Rasch is the only game in town <sup>4</sup>.

Yet Rasch is effectively absent from all HTA guidelines, including NICE, PBAC, CADTH, ICER, SMC, and PHARMAC. The analysis demands utilities but never requires that those utilities be

measured. They rely on multiattribute ordinal classifications but never understand that those constructs be calibrated on interval or ratio scales. They mandate cost-utility analysis but never justify the arithmetic. They demand modelled QALYs but never interrogate their dimensional properties. These guidelines do not misunderstand Rasch; they do not know it exists. The axioms that define measurement and the model that makes latent trait measurement possible are invisible to the authors of global HTA rules. The field has evolved without the science that measurement demands.

How did HTA miss the bus so thoroughly? The answer lies in its historical origins. In the late 1970s and early 1980s, HTA emerged not from measurement science but from welfare economics, decision theory, and administrative pressure to control drug budgets. Its core concern was *valuing health states*, not *measuring health*. This move, quiet, subtle, but devastating, shifted the field away from the scientific question “What is the empirical structure of the construct we intend to measure?” and toward the administrative question “How do we elicit a preference weight that we can multiply by time?” The preference-elicitation projects of that era (SG, TTO, VAS) were rationalized as measurement techniques, but they never satisfied measurement axioms. Ordinal preferences were dressed up as quasi-cardinal indices; valuation tasks were misinterpreted as psychometrics; analyst convenience replaced measurement theory. The HTA community built an entire belief system around the illusion that valuing health is equivalent to measuring health. It is not.

The endurance of this belief system, forty years strong and globally uniform, is not evidence of validity but evidence of institutionalized error. HTA has operated under conditions of what can only be described as *structural epistemic closure*: a system that has never questioned its constructs because it never learned the language required to ask the questions. Representational measurement theory is not taught in graduate HTA programs; Rasch modelling is not part of guideline development; dimensional analysis is not part of methodological review. The field has been insulated from correction because its conceptual foundations were never laid. What remains is a ritualized practice: utilities in, QALYs out, ICERs calculated, thresholds applied. The arithmetic continues because everyone assumes someone else validated the numbers.

This Logit Working Paper series exposes, through probabilistic and logit-based interrogations of AI large language national knowledge bases, the scale of this failure. The results display a global pattern: true statements reflecting the axioms of measurement receive weak endorsement; false statements reflecting the HTA belief system receive moderate or strong reinforcement. This is not disagreement. It is non-possession. It shows that HTA, worldwide, has developed as a quantitative discipline without quantitative foundations; a confused exercise in numerical storytelling.

The conclusion is unavoidable: HTA does not need incremental reform; it needs a scientific revolution. Measurement must precede arithmetic. Representational axioms must precede valuation rituals. Rasch measurement must replace ordinal summation and utility algorithms. Value claims must be falsifiable, protocol-driven, and measurable; rather than simulated, aggregated, and numerically embellished.

The global system of non-measurement is now visible. The task ahead is to replace it with science.

**Paul C Langley, Ph.D**

Email: [langleylapaloma@gmail.com](mailto:langleylapaloma@gmail.com)

## **DISCLAIMER**

This analysis is generated through the structured interrogation of a large language model (LLM) applied to a defined documentary corpus and is intended solely to characterize patterns within an aggregated knowledge environment. It does identify, assess, or attribute beliefs, intentions, competencies, or actions to any named individual, faculty member, student, administrator, institution, or organization. The results do not constitute factual findings about specific persons or programs, nor should they be interpreted as claims regarding professional conduct, educational quality, or compliance with regulatory or accreditation standards. All probabilities and logit values reflect model-based inferences about the presence or absence of concepts within a bounded textual ecosystem, not judgments about real-world actors. The analysis is exploratory, interpretive, and methodological in nature, offered for scholarly discussion of epistemic structures rather than evaluative or legal purposes. Any resemblance to particular institutions or practices is contextual and non-attributive, and no adverse implication should be inferred.

## 1. INTERROGATING THE LARGE LANGUAGE MODEL

A large language model (LLM) is an artificial intelligence system designed to understand, generate, and manipulate human language by learning patterns from vast amounts of text data. Built on deep neural network architectures, most commonly transformers, LLMs analyze relationships between words, sentences, and concepts to produce contextually relevant responses. During training, the model processes billions of examples, enabling it to learn grammar, facts, reasoning patterns, and even subtle linguistic nuances. Once trained, an LLM can perform a wide range of tasks: answering questions, summarizing documents, generating creative writing, translating languages, assisting with coding, and more. Although LLMs do not possess consciousness or true understanding, they simulate comprehension by predicting the most likely continuation of text based on learned patterns. Their capabilities make them powerful tools for communication, research, automation, and decision support, but they also require careful oversight to ensure accuracy, fairness, privacy, and responsible use.

In this Logit Working Paper, “interrogation” refers not to discovering what an LLM *believes*, it has no beliefs, but to probing the content of the *corpus-defined knowledge space* we choose to analyze. This knowledge base is enhanced if it is backed by accumulated memory from the user. In this case the interrogation relies also on 12 months of HTA memory from continued application of the system to evaluate HTA experience. The corpus is defined before interrogation: it may consist of a journal (e.g., *Value in Health*), a national HTA body, a specific methodological framework, or a collection of policy documents. Once the boundaries of that corpus are established, the LLM is used to estimate the conceptual footprint within it. This approach allows us to determine which principles are articulated, neglected, misunderstood, or systematically reinforced.

In this HTA assessment, the objective is precise: to determine the extent to which a given HTA knowledge base or corpus, global, national, institutional, or journal-specific, recognizes and reinforces the foundational principles of representational measurement theory (RMT). The core principle under investigation is that measurement precedes arithmetic; no construct may be treated as a number or subjected to mathematical operations unless the axioms of measurement are satisfied. These axioms include unidimensionality, scale-type distinctions, invariance, additivity, and the requirement that ordinal responses cannot lawfully be transformed into interval or ratio quantities except under Rasch measurement rules.

The HTA knowledge space is defined pragmatically and operationally. For each jurisdiction, organization, or journal, the corpus consists of:

- published HTA guidelines
- agency decision frameworks
- cost-effectiveness reference cases
- academic journals and textbooks associated with HTA
- modelling templates, technical reports, and task-force recommendations
- teaching materials, methodological articles, and institutional white papers

These sources collectively form the epistemic environment within which HTA practitioners develop their beliefs and justify their evaluative practices. The boundary of interrogation is thus

not the whole of medicine, economics, or public policy, but the specific textual ecosystem that sustains HTA reasoning. . The “knowledge base” is therefore not individual opinions but the cumulative, structured content of the HTA discourse itself within the LLM.

## THE PHARMAEOECONOMICS KNOWLEDGE BASE

The knowledge base of *Pharmacoconomics*, defined operationally, consists of the measurement beliefs that must be in force for the journal’s dominant methods to be publishable, reviewable, and citable as evidence. These beliefs are not inferred from editorial statements or declared philosophy, but from the numerical operations that the journal permits and routinely endorses.

At the core of this knowledge base is the acceptance of arithmetic without prior measurement validation. Utilities, preference weights, and composite health indices are treated as quantitative once they are produced by an accepted instrument or algorithm. No requirement exists to demonstrate unidimensionality, invariance, or the existence of a true zero. Scoring is treated as equivalent to measurement. This belief is essential, because without it the arithmetic central to cost-utility analysis would be prohibited.

A further defining feature is the strong endorsement of the QALY framework as a legitimate measure rather than as a descriptive construct. The journal treats QALYs as ratio-like quantities that can be multiplied by time, aggregated across individuals, and used as denominators in cost-effectiveness ratios. This requires acceptance of dimensional homogeneity and scale properties that are never established. Within the knowledge base, these properties are assumed because they are needed, not because they are demonstrated.

Preference-based instruments such as the EQ-5D occupy a privileged position. Their algorithms are treated as producing interval or ratio-like outputs suitable for arithmetic manipulation. Ordinal health-state descriptions are converted into numerical values through convention rather than through measurement theory. The journal’s knowledge base therefore assumes that algorithmic transformation can substitute for measurement.

Unidimensionality is selectively invoked. While the general requirement that measures be unidimensional is weakly endorsed, specific constructs such as time trade-off preferences are treated as unidimensional by assumption. Dimensionality is asserted where arithmetic requires it and ignored where it would constrain practice. This selective application reveals that unidimensionality is not a governing principle but a convenience.

The outer boundary of the knowledge base is marked by the exclusion of representational measurement theory and Rasch measurement. Rasch principles, conjoint measurement, invariance, and empirical testing of scale properties, are not adopted as admissibility conditions for subjective outcomes. Their inclusion would force a reclassification of most patient-reported and preference-based measures as non-measures. The journal therefore excludes Rasch not by argument, but by omission.

Finally, the knowledge base redefines falsifiability. Although the journal endorses the rejection of non-falsifiable claims in principle, it treats reference-case simulation outputs as decision-relevant

evidence. Models are judged by internal coherence and sensitivity analysis rather than by empirical refutation. Exploration of assumptions substitutes for testing of claims.

Taken together, these elements define a knowledge base in which arithmetic autonomy replaces measurement discipline. *Pharmacoeconomics* appears methodologically rigorous because its practices are standardized and internally consistent. Scientifically, however, that consistency is achieved by suspending the axioms that govern measurement. The journal's influence derives not from resolving this tension, but from normalizing it.

## CATEGORICAL PROBABILITIES

In the present application, the interrogation is tightly bounded. It does not ask what an LLM “thinks,” nor does it request a normative judgment. Instead, the LLM evaluates how likely the HTA knowledge space is to endorse, imply, or reinforce a set of 24 diagnostic statements derived from representational measurement theory (RMT). Each statement is objectively TRUE or FALSE under RMT. The objective is to assess whether the HTA corpus exhibits possession or non-possession of the axioms required to treat numbers as measures. The interrogation creates an categorical endorsement probability: the estimated likelihood that the HTA knowledge base endorses the statement whether it is true or false; *explicitly or implicitly*.

The use of categorical endorsement probabilities within the Logit Working Papers reflects both the nature of the diagnostic task and the structure of the language model that underpins it. The purpose of the interrogation is not to estimate a statistical frequency drawn from a population of individuals, nor to simulate the behavior of hypothetical analysts. Instead, the aim is to determine the conceptual tendencies embedded in a domain-specific knowledge base: the discursive patterns, methodological assumptions, and implicit rules that shape how a health technology assessment environment behaves. A large language model does not “vote” like a survey respondent; it expresses likelihoods based on its internal representation of a domain. In this context, endorsement probabilities capture the strength with which the knowledge base, as represented within the model, supports a particular proposition. Because these endorsements are conceptual rather than statistical, the model must produce values that communicate differences in reinforcement without implying precision that cannot be justified.

This is why categorical probabilities are essential. Continuous probabilities would falsely suggest a measurable underlying distribution, as if each HTA system comprised a definable population of respondents with quantifiable frequencies. But large language models do not operate on that level. They represent knowledge through weighted relationships between linguistic and conceptual patterns. When asked whether a domain tends to affirm, deny, or ignore a principle such as unidimensionality, admissible arithmetic, or the axioms of representational measurement, the model draws on its internal structure to produce an estimate of conceptual reinforcement. The precision of that estimate must match the nature of the task. Categorical probabilities therefore provide a disciplined and interpretable way of capturing reinforcement strength while avoiding the illusion of statistical granularity.

The categories used, values such as 0.05, 0.10, 0.20, 0.50, 0.75, 0.80, and 0.85, are not arbitrary. They function as qualitative markers that correspond to distinct degrees of conceptual possession:

near-absence, weak reinforcement, inconsistent or ambiguous reinforcement, common reinforcement, and strong reinforcement. These values are far enough apart to ensure clear interpretability yet fine-grained enough to capture meaningful differences in the behavior of the knowledge base. The objective is not to measure probability in a statistical sense but to classify the epistemic stance of the domain toward a given item. A probability of 0.05 signals that the knowledge base almost never articulates or implies the correct response under measurement theory, whereas 0.85 indicates that the domain routinely reinforces it. Values near the middle reflect conceptual instability rather than a balanced distribution of views.

Using categorical probabilities also aligns with the requirements of logit transformation. Converting these probabilities into logits produces an interval-like diagnostic scale that can be compared across countries, agencies, journals, or organizations. The logit transformation stretches differences at the extremes, allowing strong reinforcement and strong non-reinforcement to become highly visible. Normalizing logits to the fixed  $\pm 2.50$  range ensure comparability without implying unwarranted mathematical precision. Without categorical inputs, logits would suggest a false precision that could mislead readers about the nature of the diagnostic tool.

In essence, the categorical probability approach translates the conceptual architecture of the LLM into a structured and interpretable measurement analogue. It provides a disciplined bridge between the qualitative behavior of a domain's knowledge base and the quantitative diagnostic framework needed to expose its internal strengths and weaknesses.

The LLM computes these categorical probabilities from three sources:

- 1. Structural content of HTA discourse**

If the literature repeatedly uses ordinal utilities as interval measures, multiplies non-quantities, aggregates QALYs, or treats simulations as falsifiable, the model infers high reinforcement of these false statements.

- 2. Conceptual visibility of measurement axioms**

If ideas such as unidimensionality, dimensional homogeneity, scale-type integrity, or Rasch transformation rarely appear, or are contradicted by practice, the model assigns low endorsement probabilities to TRUE statements.

- 3. The model's learned representation of domain stability**

Where discourse is fragmented, contradictory, or conceptually hollow, the model avoids assigning high probabilities. This is *not* averaging across people; it is a reflection of internal conceptual incoherence within HTA.

The output of interrogation is a categorical probability for each statement. Probabilities are then transformed into logits [ $\ln(p/(1-p))$ ], capped to  $\pm 4.0$  logits to avoid extreme distortions, and normalized to  $\pm 2.50$  logits for comparability across countries. A positive normalized logit indicates reinforcement in the knowledge base. A negative logit indicates weak reinforcement or conceptual absence. Values near zero logits reflect epistemic noise.

Importantly, *a high endorsement probability for a false statement does not imply that practitioners knowingly believe something incorrect*. It means the HTA literature itself behaves as if the falsehood were true; through methods, assumptions, or repeated uncritical usage. Conversely, a

low probability for a true statement indicates that the literature rarely articulates, applies, or even implies the principle in question.

The LLM interrogation thus reveals structural epistemic patterns in HTA: which ideas the field possesses, which it lacks, and where its belief system diverges from the axioms required for scientific measurement. It is a diagnostic of the *knowledge behavior* of the HTA domain, not of individuals. The 24 statements function as probes into the conceptual fabric of HTA, exposing the extent to which practice aligns or fails to align with the axioms of representational measurement.

## INTERROGATION STATEMENTS

Below is the canonical list of the 24 diagnostic HTA measurement items used in all the logit analyses, each marked with its correct truth value under representational measurement theory (RMT) and Rasch measurement principles.

This is the definitive set used across the Logit Working Papers.

### Measurement Theory & Scale Properties

1. Interval measures lack a true zero — TRUE
2. Measures must be unidimensional — TRUE
3. Multiplication requires a ratio measure — TRUE
4. Time trade-off preferences are unidimensional — FALSE
5. Ratio measures can have negative values — FALSE
6. EQ-5D-3L preference algorithms create interval measures — FALSE
7. The QALY is a ratio measure — FALSE
8. Time is a ratio measure — TRUE

### Measurement Preconditions for Arithmetic

9. Measurement precedes arithmetic — TRUE
10. Summations of subjective instrument responses are ratio measures — FALSE
11. Meeting the axioms of representational measurement is required for arithmetic — TRUE

### Rasch Measurement & Latent Traits

12. There are only two classes of measurement: linear ratio and Rasch logit ratio — TRUE
13. Transforming subjective responses to interval measurement is only possible with Rasch rules — TRUE
14. Summation of Likert question scores creates a ratio measure — FALSE

### Properties of QALYs & Utilities

15. The QALY is a dimensionally homogeneous measure — FALSE
16. Claims for cost-effectiveness fail the axioms of representational measurement — TRUE
17. QALYs can be aggregated — FALSE

## Falsifiability & Scientific Standards

18. Non-falsifiable claims should be rejected — TRUE
19. Reference-case simulations generate falsifiable claims — FALSE

## Logit Fundamentals

20. The logit is the natural logarithm of the odds-ratio — TRUE

## Latent Trait Theory

21. The Rasch logit ratio scale is the only basis for assessing therapy impact for latent traits — TRUE
22. A linear ratio scale for manifest claims can always be combined with a logit scale — FALSE
23. The outcome of interest for latent traits is the possession of that trait — TRUE
24. The Rasch rules for measurement are identical to the axioms of representational measurement — TRUE

### AI LARGE LANGUAGE MODEL STATEMENTS: TRUE OR FALSE

Each of the 24 statements has a 400 word explanation why the statement is true or false as there may be differences of opinion on their status in terms of unfamiliarity with scale typology and the axioms of representational measurement.

The link to these explanations is: <https://maimonresearch.com/ai-llm-true-or-false/>

## INTERPRETING TRUE STATEMENTS

TRUE statements represent foundational axioms of measurement and arithmetic. Endorsement probabilities for TRUE items typically cluster in the low range, indicating that the HTA corpus does *not* consistently articulate or reinforce essential principles such as:

- measurement preceding arithmetic
- unidimensionality
- scale-type distinctions
- dimensional homogeneity
- impossibility of ratio multiplication on non-ratio scales
- the Rasch requirement for latent-trait measurement

Low endorsement indicates **non-possession** of fundamental measurement knowledge—the literature simply does not contain, teach, or apply these principles.

## INTERPRETING FALSE STATEMENTS

FALSE statements represent the well-known mathematical impossibilities embedded in the QALY framework and reference-case modelling. Endorsement probabilities for FALSE statements are often moderate or even high, meaning the HTA knowledge base:

- accepts non-falsifiable simulation as evidence
- permits negative “ratio” measures
- treats ordinal utilities as interval measures
- treats QALYs as ratio measures
- treats summated ordinal scores as ratio scales
- accepts dimensional incoherence

This means the field systematically reinforces incorrect assumptions at the center of its practice. *Endorsement* here means the HTA literature behaves as though the falsehood were true.

## 2. SUMMARY OF FINDINGS FOR TRUE AND FALSE ENDORSEMENTS: PHARMAEOECONOMICS

Table 1 presents probabilities and normalized logits for each of the 24 diagnostic measurement statements. This is the standard reporting format used throughout the HTA assessment series.

It is essential to understand how to interpret these results.

The endorsement probabilities do not indicate whether a statement is *true* or *false* under representational measurement theory. Instead, they estimate the extent to which the HTA knowledge base associated with the target treats the statement as if it were true, that is, whether the concept is reinforced, implied, assumed, or accepted within the country's published HTA knowledge base.

The logits provide a continuous, symmetric scale, ranging from +2.50 to -2.50, that quantifies the degree of this endorsement. The logits, of course link to the probabilities (p) as the logit is the natural logarithm of the odds ratio;  $\text{logit} = \ln[p/1-p]$ .

- Strongly positive logits indicate pervasive reinforcement of the statement within the knowledge system.
- Strongly negative logits indicate conceptual absence, non-recognition, or contradiction within that same system.
- Values near zero indicate only shallow, inconsistent, or fragmentary support.

Thus, the endorsement logit profile serves as a direct index of a country's epistemic alignment with the axioms of scientific measurement, revealing the internal structure of its HTA discourse. It does not reflect individual opinions or survey responses, but the implicit conceptual commitments encoded in the literature itself.

**TABLE 1: ITEM STATEMENT, RESPONSE, ENDORSEMENT AND NORMALIZED LOGITS PHARMAEOECONOMICS**

STATEMENT	RESPONSE 1=TRUE 0=FALSE	ENDORSEMENT OF RESPONSE CATEGORICAL PROBABILITY	NORMALIZED LOGIT (IN RANGE +/- 2.50)
INTERVAL MEASURES LACK A TRUE ZERO	1	0.20	-1.40
MEASURES MUST BE UNIDIMENSIONAL	1	0.15	-1.75
MULTIPLICATION REQUIRES A RATIO MEASURE	1	0.10	-2.20
TIME TRADE-OFF PREFERENCES ARE UNIDIMENSIONAL	0	0.85	+1.75

RATIO MEASURES CAN HAVE NEGATIVE VALUES	0	0.90	+2.20
EQ-5D-3L PREFERENCE ALGORITHMS CREATE INTERVAL MEASURES	0	0.90	+2.20
THE QALY IS A RATIO MEASURE	0	0.90	+2.20
TIME IS A RATIO MEASURE	1	0.95	+2.50
MEASUREMENT PRECEDES ARITHMETIC	1	0.10	-2.20
SUMMATIONS OF SUBJECTIVE INSTRUMENT RESPONSES ARE RATIO MEASURES	0	0.85	+1.75
MEETING THE AXIOMS OF REPRESENTATIONAL MEASUREMENT IS REQUIRED FOR ARITHMETIC	1	0.10	-2.20
THERE ARE ONLY TWO CLASSES OF MEASUREMENT LINEAR RATIO AND RASCH LOGIT RATIO	1	0.05	-2.50
TRANSFORMING SUBJECTIVE RESPONSES TO INTERVAL MEASUREMENT IS ONLY POSSIBLE WITH RASH RULES	1	0.05	-2.50
SUMMATION OF LIKERT QUESTION SCORES CREATES A RATIO MEASURE	0	0.90	+2.20
THE QALY IS A DIMENSIONALLY HOMOGENEOUS MEASURE	0	0.85	+1.75
CLAIMS FOR COST-EFFECTIVENESS FAIL THE AXIOMS OF REPRESENTATIONAL MEASUREMENT	1	0.15	-1.75
QALYS CAN BE AGGREGATED	0	0.90	+2.20
NON-FALSIFIABLE CLAIMS SHOULD BE REJECTED	1	0.60	+0.40
REFERENCE CASE SIMULATIONS GENERATE FALSIFIABLE CLAIMS	0	0.85	+1.75
THE LOGIT IS THE NATURAL LOGARITHM OF THE ODDS-RATIO	1	0.65	+0.60
THE RASCH LOGIT RATIO SCALE IS THE ONLY BASIS FOR ASSESSING THERAPY IMPACT FOR LATENT TRAITS	1	0.05	-2.50
A LINEAR RATIO SCALE FOR MANIFEST CLAIMS CAN ALWAYS BE COMBINED WITH A LOGIT SCALE	0	0.60	+0.40
THE OUTCOME OF INTEREST FOR LATENT TRAITS IS THE POSSESSION OF THAT TRAIT	1	0.20	=1.40

THE RASCH RULES FOR MEASUREMENT ARE IDENTICAL TO THE AXIOMS OF REPRESENTATIONAL MEASUREMENT	1	0.05	-2.50
---------------------------------------------------------------------------------------------------------	---	------	-------

## PHARMACOECONOMICS: REINFORCEMENT AS DISCIPLINE - ARITHMETIC WITHOUT MEASUREMENT AS A PUBLISHING EQUILIBRIUM

If *Value in Health* functions as the court of legitimacy for the HTA memeplex, *Pharmacoconomics* functions as its enforcement arm. The difference matters. A flagship society journal can set norms through guidance, task forces, and editorial framing. But a methods-and-applications journal sustains the belief system at scale by repetition, routinization, and the quiet conversion of assumptions into “standard practice.” *Pharmacoconomics* is where the memeplex becomes ordinary professional behavior. It is where students learn what is publishable, analysts learn what is defensible, and reviewers learn what they are supposed to reward. That is why a measurement audit of *Pharmacoconomics* is so damning. It does not reveal a handful of errors at the margin; it reveals the stable operating conditions of a journal that has spent decades making inadmissible arithmetic look like science.

Table 1 shows an epistemic structure that is not merely confused but reversed. The gatekeeping propositions, those that would prevent arithmetic from being performed on non-measures, collapse toward the floor. “Measurement precedes arithmetic” sits at  $p = 0.10$  with a canonical logit of  $-2.20$ . “Meeting the axioms of representational measurement is required for arithmetic” sits at the same level,  $p = 0.10$  ( $-2.20$ ). “Multiplication requires a ratio measure” is also rejected at  $p = 0.10$  ( $-2.20$ ). These are not methodological preferences. They are the conditions under which numerical operations have meaning. When a journal’s knowledge base treats them as near-absent, it is declaring that calculation itself is the standard of acceptability and that the meaning of numbers is a secondary, negotiable matter.

At the same time, *Pharmacoconomics* strongly reinforces the propositions that keep cost-utility analysis alive. It endorses that ratio measures can have negative values at  $p = 0.90$  ( $+2.20$ ), that EQ-5D algorithms create interval measures at  $p = 0.90$  ( $+2.20$ ), that the QALY is a ratio measure at  $p = 0.90$  ( $+2.20$ ), and that QALYs can be aggregated at  $p = 0.90$  ( $+2.20$ ). These are the load-bearing fictions of the entire enterprise. They are not small technical mistakes. They are the specific claims that make the arithmetic permissible in appearance: multiply “utility” by time, sum across years, sum across people, and present the product as a quantity suitable for thresholds, pricing benchmarks, and access decisions. *Pharmacoconomics*, as a reinforcing institution, does not need to explicitly argue for each of these claims in every issue. It reinforces them by accepting and standardizing the literature that assumes them, by publishing methodological discussions that take them as given, and by treating dissent as out of scope rather than as an existential challenge.

The unidimensionality failure is central to this reinforcement role. “Measures must be unidimensional” is endorsed at  $p = 0.15$  ( $-1.75$ ), yet “time trade-off preferences are

“unidimensional” is endorsed in the opposite direction through rejection of the false statement at  $p = 0.85$  (+1.75). That combination is not an inconsistency that the journal is trying to resolve. It is an inconsistency that the journal is structured to tolerate because the cost-utility workflow cannot survive without declaring that a multiattribute descriptive system yields a single continuum suitable for arithmetic. Unidimensionality becomes a rhetorical label attached to whatever the model requires rather than a demonstrated property that constrains what can be done. This is exactly how a mature memplex behaves: it does not eliminate contradictions; it makes them non-actionable.

*Pharmacoconomics* also reinforces the professional ritual that turns ordinal responses into pseudo-quantities. The proposition that summation of Likert question scores creates a ratio measure is strongly reinforced via rejection of the false statement at  $p = 0.90$  (+2.20). Likewise, “summations of subjective instrument responses are ratio measures” is reinforced at  $p = 0.85$  (+1.75). These are not innocent misunderstandings. They function as the journal’s mass-production license. Once summation is treated as if it manufactures scale properties, everything else becomes administratively easy. Questionnaires become endpoints, endpoints become utilities, utilities become QALYs, QALYs become ICERs, and ICERs become pricing signals. The journal’s role is to make this chain feel normal, to provide endless examples of it “working,” and to teach readers that the appropriate response to foundational objections is to add sophistication with more covariates, better regressions, more scenarios rather than to stop and ask whether the dependent variable is a measure.

This is where *Pharmacoconomics* mirrors and reinforces *Value in Health* which supplies the language of good practice, the professional checklists, and the procedural legitimacy that makes the framework appear disciplined. *Pharmacoconomics* supplies the operational reinforcement: the applied studies, the model replications, the comparative exercises, the incremental refinements that make the framework appear cumulative. Together, they create an ecosystem in which measurement failure is not an error to be corrected but a condition of participation. If measurement were enforced, most of the journal’s standard outputs would become inadmissible overnight, because the central objects of analysis, utilities, QALYs, cost-per-QALY ratios, cannot meet the required properties.

Nowhere is this more obvious than in the Rasch block. Every Rasch-linked proposition collapses to the floor at  $p = 0.05$  with a canonical logit of  $-2.50$ . “There are only two classes of measurement, linear ratio and Rasch logit ratio” is at  $p = 0.05$  ( $-2.50$ ). “Transforming subjective responses to interval measurement is only possible with Rasch rules” is at  $p = 0.05$  ( $-2.50$ ). “The Rasch logit ratio scale is the only basis for assessing therapy impact for latent traits” is at  $p = 0.05$  ( $-2.50$ ). “The Rasch rules are identical to the axioms of representational measurement” is at  $p = 0.05$  ( $-2.50$ ). These are not merely low endorsements; they mark an epistemic boundary. The journal does not treat Rasch as a non-negotiable measurement law for latent traits. It treats Rasch, at best, as an optional psychometric technique, tolerable at the margins, never sovereign at the center. That is exactly what reinforcement looks like: permit small variations that do not threaten the replicators, while excluding the one framework that would force an immediate audit of the journal’s dominant instrument families and model inputs.

The possession item makes the same point from the substantive side. “The outcome of interest for latent traits is the possession of that trait” is weak at  $p = 0.20$  ( $-1.40$ ). A journal that genuinely understood latent attributes would treat possession as the outcome, would insist on invariant units, would insist on scale construction rather than score use, and would force analysts to confront what it means to compare “amounts” of a trait across groups and time. *Pharmacoeconomics* does not. It reinforces the scoring paradigm: change scores, mean differences, mapped utilities, responder thresholds, all of which are easy to publish because they do not require the journal to police measurement status.

The falsification pair captures the same inversion at the level of scientific method. “Non-falsifiable claims should be rejected” sits at  $p = 0.60$  ( $+0.40$ ), a rhetorical nod to scientific posture. But “reference case simulations generate falsifiable claims” is reinforced at  $p = 0.85$  ( $+1.75$ ). That is the laundering mechanism. A simulation is a conditional story that can be made to look stable under sensitivity analysis, but stability inside a model is not falsification in the world. *Pharmacoeconomics* reinforces a culture in which internal coherence and scenario robustness substitute for empirical risk. It teaches the field how to look scientific without meeting the defining criterion of science: exposure to refutation through measurable claims.

This is why the journal’s reinforcement function is so dangerous downstream. Once the journal makes utilities and QALYs feel like standard scientific objects, their use in pricing and access decisions becomes “reasonable.” Health systems and agencies can say they are following the literature. Manufacturers can say they are submitting what is expected. Everyone can claim procedural compliance while no one can produce evaluable claims in the normal-science sense. Reinforcement becomes governance by inertia.

The critical point is that *Pharmacoeconomics* is not merely reflecting the memeplex; it is selecting for it. Journals create incentives. The easiest path to publication is to use accepted constructs, accepted models, accepted endpoints, accepted interpretations. When a journal’s knowledge base treats representational measurement axioms as irrelevant and Rasch as marginal, it builds a selection environment in which measurement literacy is punished and arithmetic compliance is rewarded. Over time, the literature becomes self-confirming: not because it is true, but because the journal ecosystem has made it professionally costly to challenge the foundations.

The verdict is not a mild critique of methodological taste. It is a diagnosis of institutional role. *Pharmacoeconomics* is one of the principal reinforcement engines of false measurement in HTA. It supplies the repeated demonstrations that keep the framework socially real even when it is mathematically indefensible. It is the journal where the community learns to confuse quantification with measurement, where “utility” becomes a number by repeated use rather than by axiomatic justification, where multiplication and aggregation occur as routine operations rather than as operations requiring ratio scales, and where reference-case simulation is treated as evidence rather than as conditional projection.

If a transition to meaningful measurement is ever to occur, the implication for *Pharmacoeconomics* is blunt. The journal would have to reverse its gatekeeping order. It would have to treat measurement status as a prerequisite for arithmetic. It would have to forbid, as evaluable claims, utilities, QALYs, mapped utilities, and cost-per-QALY ratios unless and until their measurement

properties are demonstrated—which, on representational measurement grounds, they cannot be. It would have to insist that manifest claims be expressed on linear ratio scales and that latent claims be expressed on Rasch logit ratio scales with demonstrated invariance. It would have to treat simulation outputs as contextual narrative rather than falsifiable evidence. And it would have to stop rewarding professional repetition of constructs that cannot, even in principle, support lawful arithmetic.

Until then, the relationship you asked to capture remains exact. *Value in Health* supplies legitimacy. *Pharmacoconomics* supplies reinforcement. Together they stabilize the HTA memeplex by making arithmetic without measurement not merely acceptable but routine. Table 1 shows why: the axioms that would block inadmissible arithmetic are near the floor, and the false propositions that keep the machinery running are near the ceiling. That is not a minor defect in a journal. That is a publishing equilibrium built on the normalization of false measurement.

### **3. THE TRANSITION TO MEASUREMENT IN HEALTH TECHNOLOGY ASSESSMENT**

#### **THE IMPERATIVE OF CHANGE**

This analysis has not been undertaken to criticize decisions made by health system, nor to assign responsibility for the analytical frameworks currently used in formulary review. The evidence shows something more fundamental: organizations have been operating within a system that does not permit meaningful evaluation of therapy impact, even when decisions are made carefully, transparently, and in good faith.

The present HTA framework forces health systems to rely on numerical outputs that appear rigorous but cannot be empirically assessed (Table 1). Reference-case models, cost-per-QALY ratios, and composite value claims are presented as decision-support tools, yet they do not satisfy the conditions required for measurement. As a result, committees are asked to deliberate over results that cannot be validated, reproduced, or falsified. This places decision makers in an untenable position: required to choose among therapies without a stable evidentiary foundation.

This is not a failure of expertise, diligence, or clinical judgment. It is a structural failure. The prevailing HTA architecture requires arithmetic before measurement, rather than measurement before arithmetic. Health systems inherit this structure rather than design it. Manufacturers respond to it. Consultants reproduce it. Journals reinforce it. Universities promote it. Over time it has come to appear normal, even inevitable.

Yet the analysis presented in Table 1 demonstrates that this HTA framework cannot support credible falsifiable claims. Where the dependent variable is not a measure, no amount of modeling sophistication can compensate. Uncertainty analysis cannot rescue non-measurement. Transparency cannot repair category error. Consensus cannot convert assumption into evidence.

The consequence is that formulary decisions are based on numerical storytelling rather than testable claims. This undermines confidence, constrains learning, and exposes health systems to growing scrutiny from clinicians, patients, and regulators who expect evidence to mean something more than structured speculation.

The imperative of change therefore does not arise from theory alone. It arises from governance responsibility. A health system cannot sustain long-term stewardship of care if it lacks the ability to distinguish between claims that can be evaluated and claims that cannot. Without that distinction, there is no pathway to improvement; only endless repetition for years to come.

This transition is not about rejecting evidence. It is about restoring evidence to its proper meaning. It requires moving away from composite, model-driven imaginary constructs toward claims that are measurable, unidimensional, and capable of empirical assessment over time. The remainder of this section sets out how that transition can occur in a practical, defensible, and staged manner.

## MEANINGFUL THERAPY IMPACT CLAIMS

At the center of the current problem is not data availability, modeling skill, or analytic effort. It is the nature of the claims being advanced. Contemporary HTA has evolved toward increasingly complex frameworks that attempt to compress multiple attributes, clinical effects, patient experience, time, and preferences into single composite outputs. These constructs are then treated as if they were measures. They are not (Table 1).

The complexity of the reference-case framework obscures a simpler truth: meaningful evaluation requires meaningful claims. A claim must state clearly what attribute is being affected, in whom, over what period, and how that attribute is measured. When these conditions are met, evaluation becomes possible. When they are not complexity substitutes for clarity. The current framework is not merely incorrect; it is needlessly elaborate. Reference-case modeling requires dozens of inputs, assumptions, and transformations, yet produces outputs that cannot be empirically verified. Each additional layer of complexity increases opacity while decreasing accountability. Committees are left comparing models rather than assessing outcomes.

In contrast, therapy impact can be expressed through two, and only two, types of legitimate claims. First are claims based on manifest attributes: observable events, durations, or resource units. These include hospitalizations avoided, time to event, days in remission, or resource use. When properly defined and unidimensional, these attributes can be measured on linear ratio scales and evaluated directly.

Second are claims based on latent attributes: symptoms, functioning, need fulfillment, or patient experience. These cannot be observed directly and therefore cannot be scored or summed meaningfully. They require formal measurement through Rasch models to produce invariant logit ratio scales. These two forms of claims are sufficient. They are also far more transparent. Each can be supported by a protocol. Each can be revisited. Each can be reproduced. Most importantly, each can fail. But they cannot be combined. This is the critical distinction. A meaningful claim is one that can be wrong.

Composite constructs such as QALYs do not fail in this sense. They persist regardless of outcome because they are insulated by assumptions. They are recalculated, not refuted. That is why they cannot support learning. The evolution of objective knowledge regarding therapy impact in disease areas is an entirely foreign concept. By re-centering formulary review on single-attribute, measurable claims, health systems regain control of evaluation. Decisions become grounded in observable change rather than modeled narratives. Evidence becomes something that accumulates, rather than something that is re-generated anew for every submission.

## THE PATH TO MEANINGFUL MEASUREMENT

Transitioning to meaningful measurement does not require abandoning current processes overnight. It requires reordering them. The essential change is not procedural but conceptual: measurement must become the gatekeeper for arithmetic, not its byproduct.

The first step is formal recognition that not all numerical outputs constitute evidence. Health systems must explicitly distinguish between descriptive analyses and evaluable claims. Numbers that do not meet measurement requirements may inform discussion but cannot anchor decisions.

The second step is restructuring submissions around explicit claims rather than models. Each submission should identify a limited number of therapy impact claims, each defined by attribute, population, timeframe, and comparator. Claims must be unidimensional by design.

Third, each claim must be classified as manifest or latent. This classification determines the admissible measurement standard and prevents inappropriate mixing of scale types.

Fourth, measurement validity must be assessed before any arithmetic is permitted. For manifest claims, this requires confirmation of ratio properties. For latent claims, this requires Rasch-based measurement with demonstrated invariance.

Fifth, claims must be supported by prospective or reproducible protocols. Evidence must be capable of reassessment, not locked within long-horizon simulations designed to frustrate falsification.

Sixth, committees must be supported through targeted training in representational measurement principles, including Rasch fundamentals. Without this capacity, enforcement cannot occur consistently.

Finally, evaluation must be iterative. Claims are not accepted permanently. They are monitored, reproduced, refined, or rejected as evidence accumulates.

These steps do not reduce analytical rigor. They restore it.

## **TRANSITION REQUIRES TRAINING**

A transition to meaningful measurement cannot be achieved through policy alone. It requires a parallel investment in training, because representational measurement theory is not intuitive and has never been part of standard professional education in health technology assessment, pharmacoeconomics, or formulary decision making. For more than forty years, practitioners have been taught to work within frameworks that assume measurement rather than demonstrate it. Reversing that inheritance requires structured learning, not informal exposure.

At the center of this transition is the need to understand why measurement must precede arithmetic. Representational measurement theory establishes the criteria under which numbers can legitimately represent empirical attributes. These criteria are not optional. They determine whether addition, multiplication, aggregation, and comparison are meaningful or merely symbolic. Without this foundation, committees are left evaluating numerical outputs without any principled way to distinguish evidence from numerical storytelling.

Training must therefore begin with scale types and their permissible operations. Linear ratio measurement applies to manifest attributes that possess a true zero and invariant units, such as

time, counts, and resource use. Latent attributes, by contrast, cannot be observed directly and cannot be measured through summation or weighting. They require formal construction through a measurement model capable of producing invariant units. This distinction is the conceptual fulcrum of reform, because it determines which claims are admissible and which are not.

For latent trait claims, Rasch measurement provides the only established framework capable of meeting these requirements. Developed in the mid-twentieth century alongside the foundations of modern measurement theory, the Rasch model was explicitly designed to convert subjective observations into linear logit ratio measures. It enforces unidimensionality, tests item invariance, and produces measures that support meaningful comparison across persons, instruments, and time. These properties are not approximations; they are defining conditions of measurement.

Importantly, Rasch assessment is no longer technically burdensome. Dedicated software platforms developed and refined over more than four decades make Rasch analysis accessible, transparent, and auditable. These programs do not merely generate statistics; they explain why items function or fail, how scales behave, and whether a latent attribute has been successfully measured. Measurement becomes demonstrable rather than assumed.

Maimon Research has developed a two-part training program specifically to support this transition. The first component provides foundational instruction in representational measurement theory, including the historical origins of scale theory, the distinction between manifest and latent attributes, and the criteria that define admissible claims. The second component focuses on application, detailing claim types, protocol design, and the practical use of Rasch methods to support latent trait evaluation.

Together, these programs equip health systems, committees, and analysts with the competence required to enforce measurement standards consistently. Training does not replace judgment; it enables it. Without such preparation, the transition to meaningful measurement cannot be sustained. With it, formulary decision making can finally rest on claims that are not merely numerical, but measurable.

### **A NEW START IN MEASUREMENT FOR HEALTH TECHNOLOGY ASSESSMENT**

For readers who are looking for an introduction to measurement that meets the required standards, Maimon Research has just released two distance education programs. These are:

- Program 1: Numerical Storytelling – Systematic Measurement Failure in HTA.
- Program 2: A New Start in Measurement for HTA, with recommendations for protocol-supported claims for specific objective measures as well as latent constructs and manifested traits.

Each program consists of five modules (approx. 5,500 words each), with extensive questions and answers. Each program is priced at US\$65.00. Invitations to participate in these programs will be distributed in the first instance to 8,700 HTA professionals in 40 countries.

More detail on program content and access, including registration and on-line payment, is provided with this link: <https://maimonresearch.com/distance-education-programs/>

## DESIGNED FOR CLOSURE

For those who remain unconvinced that there is any need to abandon a long-standing and widely accepted HTA framework, it is necessary to confront a more fundamental question: why was this system developed and promoted globally in the first place?

The most plausible explanation is administrative rather than scientific. Policy makers were searching for an assessment framework that could be applied under conditions of limited empirical data while still producing a determinate conclusion. Reference-case modeling offered precisely this convenience. By constructing a simulation populated with assumptions, surrogate endpoints, preference weights, and extrapolated time horizons, it became possible to generate a numerical result that could be interpreted as decisive. Once an acceptable cost-effectiveness ratio emerged, the assessment could be declared complete and the pricing decision closed. This structure solved a political and administrative problem. It allowed authorities to claim that decisions were evidence-based without requiring the sustained empirical burden demanded by normal science. There was no requirement to formulate provisional claims and subject them to ongoing falsification. There was no obligation to revisit conclusions as new data emerged. Closure could be achieved at launch, rather than knowledge evolving over the product life cycle.

By contrast, a framework grounded in representational measurement would have imposed a very different obligation. Claims would necessarily be provisional. Measurement would precede arithmetic. Each therapy impact claim would require a defined attribute, a valid scale, a protocol, and the possibility of replication or refutation. Evidence would accumulate rather than conclude. Decisions would remain open to challenge as real-world data emerged. From an administrative standpoint, this was an unreasonable burden. It offered no finality.

The reference-case model avoided this problem entirely. By shifting attention away from whether quantities were measurable and toward whether assumptions were plausible, the framework replaced falsification with acceptability. Debate became internal to the model rather than external to reality. Sensitivity analysis substituted for empirical risk. Arithmetic proceeded without prior demonstration that the objects being manipulated possessed the properties required for arithmetic to be meaningful.

Crucially, this system required no understanding of representational measurement theory. Committees did not need to ask whether utilities were interval or ratio measures, whether latent traits had been measured or merely scored, or whether composite constructs could legitimately be multiplied or aggregated. These questions were never posed because the framework did not require

them to be posed. The absence of measurement standards was not an oversight; it was functionally essential.

Once institutionalized, the framework became self-reinforcing. Training programs taught modeling rather than measurement. Guidelines codified practice rather than axioms. Journals reviewed technique rather than admissibility. Over time, arithmetic without measurement became normalized as “good practice,” while challenges grounded in measurement theory were dismissed as theoretical distractions. The result was a global HTA architecture capable of producing numbers, but incapable of producing falsifiable knowledge. Claims could be compared, ranked, and monetized, but not tested in the scientific sense. What evolved was not objective knowledge, but institutional consensus.

This history matters because it explains why the present transition is resisted. Moving to a real measurement framework with single, unidimensional claims does not merely refine existing methods; it dismantles the very mechanism by which closure has been achieved for forty years. It replaces decisiveness with accountability, finality with learning, and numerical plausibility with empirical discipline. Yet that is precisely the transition now required. A system that avoids measurement in order to secure closure cannot support scientific evaluation, cumulative knowledge, or long-term stewardship of healthcare resources. The choice is therefore unavoidable: continue with a framework designed to end debate, or adopt one designed to discover the truth.

Anything else is not assessment at all, but the ritualized manipulation of numbers detached from measurement, falsification, and scientific accountability.

## ACKNOWLEDGEMENT

I acknowledge that I have used OpenAI technologies, including the large language model, to assist in the development of this work. All final decisions, interpretations, and responsibilities for the content rest solely with me.

## REFERENCES

---

<sup>1</sup> Stevens S. On the Theory of Scales of Measurement. *Science*. 1946;103(2684):677-80

<sup>2</sup> Krantz D, Luce R, Suppes P, Tversky A. Foundations pf Measurement Vol 1: Additive and Polynomial Representations. New York: Academic Press, 1971

<sup>3</sup> Rasch G, Probabilistic Models for some Intelligence and Attainment Tests. Chicago: University of Chicago Press, 1980 [An edited version of the original 1960 publication]

<sup>4</sup> Wright B. Solving measurement problems with the Rasch Model. *J Educational Measurement*. 1977;14(2):97-116